Five-year survival of patients with stage IV epithelial ovarian carcinoma not treated after recurrence is almost nonexistent in oncological literature. The authors report a patient almost 30 years after surgery of the primary epithelial ovarian carcinoma lesion and 15 years after recurrent disease and incomplete chemotherapy who is alive without evidence of disease. She received no conventional oncological therapy during the past 15 years but rather used many types of alternative medicine, predominantly mindbody therapies. The authors review the relevant literature on this subject and describe what they believe to be the first report of long-term survival of such a patient.
Epithelial ovarian carcinoma (EOC) represents a clinically significant health problem in Western countries, ranking fifth highest in cancer incidence and fourth highest in site-specific causes of cancer deaths in women. In the United States, approximately 25 000 new ovarian cancer cases and 16 000 ovarian cancer deaths were expected in 2004. 1 Although ovarian cancer is potentially curable by surgery and chemotherapy, most cases are still diagnosed at advanced stages, and the 5-year overall survival of stage IV patients with recurrent disease not treated by chemotherapy is almost nonexistent. At that time, a biopsy from the left supraclavicular area revealed a mucoid adenocarcinoma. Chest x-ray showed a small amount of fluid in the left pleura. X-rays of the upper gastrointestinal (GI) tract were normal. She underwent laparotomy, during which a mass was found adjacent to the uterus, and a primary ovarian tumor was suspected. After reviewing the pathological slides, it was decided that the primary lesion was probably in the GI tract. Chemotherapy with 5-FU was started and continued for 5 months, and a clinical complete response was achieved. In September 1975, an enlarged lymph node in the left axilla reappeared while the patient was still on chemotherapy. Cyclophosphamide was added to the 5-FU, and there was a second complete clinical remission after 4 months of this treatment. She continued to receive the combined chemotherapy for an additional month. The ascites reappeared in June 1977, and she received for 6 months a course of adriamycin, but only a partial response was achieved. The abdominal disease progressed, and in May 1978, she was given a combination of methotrexate, cyclophosphamide, vincristine, and prednisone, which led to a partial remission. In August 1978, 2 masses were palpated in the pelvis, and the patient underwent a total abdominal hysterectomy (TAH) and bilateral salpingooophorectomy (BSO). Pathology revealed a welldifferentiated adenocarcinoma in both ovaries with cytological positive ascites. At that time, chemotherapy with cisplatinum was offered to the patient, but she refused it and any other conventional treatment after having been told by her oncologist that her life expectancy was estimated as being about 3 months.
Case Report
The patient was essentially asymptomatic until the end of 1991, when a subcutaneous mass, about 2 cm in diameter, was detected in the lower right abdomen. The fine-needle aspiration biopsy results were compatible with ovarian carcinoma. Other tests including blood biochemistry, tumor markers, and chest and abdomen computerized tomographic scans were normal. In December 1991, the patient underwent a wide resection of this abdominal mass. Laparoscopy revealed 3 small (<5 mm each) peritoneal nodules, and pathological examination showed malignant cells in 2 of them. She refused to undergo the recommended platinum-based chemotherapy and embarked on intensive use of many types of mind-body therapies, predominantly the Reich technique and dance therapy.
Currently, almost 27 years later, the patient is well and free of symptoms and any clinical sign of cancer.
Discussion
We describe a very young patient who essentially failed several lines of chemotherapy for an apparent primary ovarian malignancy and who, 27 years after abdominal surgery without any adjuvant chemotherapy, is alive and clinically free of disease. She had undergone TAH + BSO, which would be considered as being inadequate surgery according to current standard guidelines of treatment. In addition, she did not receive any oncological therapy despite having laparotomy-positive ascites.
This case represents a very rare outcome in the oncological literature. In a review of 192 patients 2 with stage IV EOC as defined in 1985 by the International Federation of Gynecology and Obstetrics, the 5-year survival rate was 7.6%, with only 6 patients surviving more than 5 years. In that report, 25 patients (14.8%) were left with only microscopic residual disease or less than 2 cm of macroscopic residual disease, 13 were disease free after surgery (2 became long-term survivors), 13 had residual disease less than 2 cm (1 survived long term), and 12 had residual disease greater than 2 cm after interval debulking surgery. The median progression-free survival was 7.1 months, and the median overall survival was 13.4 months. Univariate and multivariate analysis showed that the parameters associated with a shorter survival time were visceral involvement (lung or liver) and diagnosis before 1984. Six patients (age range, 41-54 years) survived more than 5 years: all of them received platinum-containing regimens.
In another recent published analysis, 3 the authors described long-term survival in patients with stage III to IV ovarian cancer treated about the same time as our patient but with very good conventional therapy (platinum including chemotherapy or whole abdominal radiation). Overall survival of their patients was 21% at 5 years, 13.5% at 10 years, and 12% at 15 years. The important prognostic factors for long-term survival were disease-free or minimal residual disease (a single remaining deposit <2 cm) at initial surgery with tumor grade 1 and good performance status. Compared with the normal population (1995 data), the ratio of observed to expected deaths after the start of chemotherapy at 5 years was 14.1 (P < .001), 4.9 at 9 to 10 years (P = .0033), dropping to 2.75 at 11 to 15 years (P = .090). In this study, patients with advanced cancer of the ovary who survive 11 years or longer have a life expectancy that is very similar to that of the normal population of women of the same age.
In another recent large population-based study, 4 survival following ovarian cancer was poor, with only 33% of women surviving 5 years. Stage was the strongest predictor of survival, and women diagnosed with stage III or IV disease had 5-year survival estimates of 28% and 10%, respectively, similar to figures in other reports. 5, 6 Having either poorly differentiated tumors or unknown grade tumors was associated with decreased survival, and this effect held after controlling for multiple factors including stage. The impact of grade on survival remains inconsistent, however, with several studies having reported that the influence of grade on survival disappears in multivariate analysis. [7] [8] [9] Kosary examined more than 21 000 cases reported to Surveillance, Epidemiology, and End Results between 1973 and 1987 and found that after adjusting for multiple factors, the relative risk of death increased significantly by 24% for moderately differentiated cases and by 104% for poorly differentiated cases, compared to well-differentiated cases. 9 It may be that the smaller studies lacked the statistical power to identify any significant effect of grade. As with grade, the impact of histology on survival is inconclusive in the published literature. In Kosary's study, only clear cell histology differed significantly from the reference group of endometrioid histology. Adjusting for stage, chemotherapy, and comorbidity considerably decreased the risk of death associated with being 75 years or older, but elderly women still had twice the risk of dying from ovarian cancer compared to young women. Similar to stage, the prognostic importance of age is well known, with the risk of death from ovarian carcinoma highest in elderly patients. The distribution of chemotherapy by grade mirrored that of stage: 74% of women with well-differentiated disease were treated compared to 80% to 89% of women with other grades. Chemotherapy was associated with improved survival in women with advanced-stage disease but not for those with early-stage disease. According to Kosary's findings, advanced age continues to be associated with decreased survival even with consideration of treatment and comorbid illness. Moreover, women with comorbid conditions were at 1.4 times the risk of death compared with women with no other health conditions. The results of that study also suggest that there may be major regional differences in cancer survival. American and European studies of survival trends have shown an increase in survival for younger but not older women, from the 1970s to the 1990s. Regional variation has been previously reported in a study of US mortality trends, different health services, or Northern European ancestry. 6 Regional differences were also reported in a EUROCARE study of 17 European countries, with women in Eastern European countries having markedly decreased rates of survival.
Complementary and alternative medicine (CAM) is becoming increasingly popular, particularly among patients with cancer. Ernst and Cassileth systematically reviewed the use of CAM among cancer patients as reported in 26 studies from 13 countries. 10 The average rate of CAM use was 31.4%, with rates ranging from 7% to 64%. Higher rates of CAM use were reported by women with gynecological and/or breast malignancies. 11, 12 CAM encompasses a wide range of treatment modalities, which the National Center for Complementary and Alternative Medicine (NCCAM) 13 classifies into 5 categories:
1. alternative medical systems, which are whole medical systems that are built on complete systems of theory and practice (eg, homeopathic, naturopathic, and traditional Chinese medicine); 2. mind-body interventions, which include a variety of techniques designed to enhance the mind's capacity to affect bodily function and symptoms (eg, meditation, prayer, mental healing, and art therapy); 3. biologically based therapies, which include biological substances found in nature (such as herbs, foods, and vitamins); 4. manipulative and body-based methods, including manipulation and/or movement techniques of 1 or more parts of the body (eg, chiropractic, osteopathic manipulation, and massage); and 5. energy therapies, intended to affect energy fields that allegedly surround and penetrate the human body by applying pressure and/or manipulating the body through these fields (examples include qi gong, Reiki, and Therapeutic Touch).
The objectives of CAM treatments are diverse and include reduction of radiochemotherapy-associated toxicity, improvement of cancer-related symptoms, enhancing of the immune system, and even direct antineoplastic effects. 14 Recent clinical trials have generated data on the efficacy of CAM mainly in improvement of chemotherapy-associated toxicity and cancer-related symptoms, but evidence-based data on the effect of most CAM modalities on disease recurrence and survival are lacking. 15, 16 Application of CAM-based approaches was reported as being beneficial in cancer patients in chemotherapy-associated nausea and vomiting, 17 pain, 18 fatigue, 19 relaxation, 20, 21 and anxiety and mood disturbances (for a review, see Deng and Cassileth 22 ). Furthermore, prominent cancer centers, such as M.D. Anderson (Houston, Tex), Dana-Farber (Boston, Mass), and Memorial Sloan-Kettering (New York, NY), currently employ protocols that integrate conventional and complementary medicine for oncological patients.
The patient reported in this article made intensive use of mind-body modalities, predominantly the Reich technique and dance therapy.
According to the NCCAM, mind-body medicine focuses "on the interactions among the brain, mind, body, and behavior, and the powerful ways in which emotional, mental, social, spiritual, and behavioral factors can directly affect health." 13 Mind-body interventions constitute more than 30% of the adult US population's use of CAM. 23 Evidence from multiple studies with various types of cancer patients suggests that mind-body interventions can reduce pain and improve quality of life. [24] [25] [26] Several mind-body therapies were also reported to enhance the immune system. [27] [28] [29] Reichian therapy 30 is an original body-oriented psychotherapy, developed by the Austrian psychoanalyst Dr Wilhelm Reich, who worked closely with Sigmund Freud. He employed many Freudian concepts in his work, but unlike Freud, he applied mainly body work and breathing techniques in his therapies. Reich described the tendency of the body to hold on to emotional and psychological stress as "armoring." Reich believed that physical armor develops from the chronic tightening of the muscles of the body to prevent the expression of the emotion that is being suppressed and prohibited. For example, a stiff neck can be due to the tightening of the neck muscles that prevents the patient from freely expressing the words or emotions (such as crying) that he or she does not allow himself or herself to express. Breathing work, deep tissue massage, and communication can be used for an emotional release.
The use of dance in the context of healing has been reported in ancient societies in which dance was used in spiritual growth and healing rituals. 31 Dance therapy is described by the American Cancer Society 32 as "therapeutic use of movement to improve the mental and physical well being of a person which focuses on the connection between the mind and body to promote health and healing." It was proposed by several authors that dance therapy may enhance the healing process by helping to (1) develop positive body image and self-esteem; (2) decrease stress, anxiety, and depression; (3) reduce chronic pain and body tension; (4) decrease isolation, increase communication skills, and enhance interpersonal interaction; and (5) encourage a sense of well-being and completeness. 33, 34 Several nonrandomized small trials have shown a benefit for dance therapy in psychological and spiritual adaptation 35, 36 to breast cancer. Sandel et al 37 recently assessed the efficacy effect of a dance and movement program on quality of life and shoulder function in breast cancer survivors treated within the preceding 5 years. Thirty-five women completed a 12-week intervention, using the Lebed method, which focuses on healing through movement and dance. The study design was a randomized controlled crossover trial, and the analysis of the results showed that breast cancer quality of life was significantly improved in the intervention group compared to the control group.
We are not aware of any published report on long-term, disease-free survival of a patient with stage IV ovarian cancer and recurrent disease not treated by aggressive chemotherapy after surgery. The patient we describe is now 27 years after first diagnosis and recurrences and remains clinically free of disease. Based on this report and the data in the literature, we recommend further scientific research to assess the efficacy of CAM modalities for patients with cancer.
